Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici

doi:10.4330/wjc.v16.i10.550

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2378)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

HTML

1678

Figures (1-2)

Tables (1-2)

Sum=1877

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

121

Sum=212

Publishing Process of This Article

Item

Count

Browse

Download

Sum=50

Oct 26, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Cardiol. Oct 26, 2024; 16(10): 550-563
Published online Oct 26, 2024. doi: 10.4330/wjc.v16.i10.550

Open in New Tab Full Size Figure Download Figure

Figure 1 Mechanism of action of sodium glucose cotransporter-2 inhibitors in heart failure. EPO: Erythropoietin; O₂: Oxygen; RBC: Red blood cell.

Open in New Tab Full Size Figure Download Figure

Figure 2 Roadmap of various landmark trials of sodium glucose cotransporter-2 inhibitors in heart failure. HF: Heart failure; MI: Myocardial infarction; EF: Ejection fraction.

Citation: Bhandari M, Pradhan A, Vishwakarma P, Singh A, Sethi R. Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici. World J Cardiol 2024; 16(10): 550-563
URL: https://www.wjgnet.com/1949-8462/full/v16/i10/550.htm
DOI: https://dx.doi.org/10.4330/wjc.v16.i10.550